Business
Optimi Health Announces Proposed Nasdaq Listing and U.S. Underwritten Public Offering
Vancouver, British Columbia--(Newsfile Corp. - March 16, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and distributing finished psychedelic drug products, today announced that it has commenced an underwritten public offering in the United States (the "Offering") of its common shares, no par value (the "Shares"), pursuant to a registration statement filed with the United States...
About this update from Optimi Health Corp.
[{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - March 16, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and distributing finished psychedelic drug products, today announced that it has commenced an underwritten public offering in the United States (the "Offering") of its common shares, no par value (the "Shares"), pursuant to a registration statement filed with the United States Securities and Exchange Commission (the "SEC"), in connection with its proposed listing on the Nasdaq Capital Market ("Nasdaq").","length":685,"tagName":"p"},{"type":"text","content":"Joseph Gunnar & Co., LLC is acting as sole book-running manager for the proposed Offering. In connection with the proposed Offering, the Company has applied to list its Shares on the Nasdaq under the symbol "OPTH". Subject to approval of the Nasdaq listing and completion of the Offering, the Company's Shares, including those currently trading on the Canadian Securities Exchange ("CSE"), are expected to be listed for trading on the Nasdaq while continuing to trade on the CSE.","length":507,"tagName":"p"},{"type":"text","content":"The Offering will be made only by means of a prospectus that forms a part of an effective registration statement in the United States and pursuant to the public offering exemption available under BC Instrument 72-503 - Distribution of Securities outside British Columbia in Canada. When available, copies of the preliminary prospectus relating to this Offering may be obtained from Joseph Gunnar & Co., LLC, Prospectus Department, 40 Wall Street, 30th Floor, New York, NY 10005, telephone 212-440-9600, email: [email protected].","length":537,"tagName":"p"},{"type":"text","content":"A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation...